Treatment of ulcerative colitis

Current Opinion in Gastroenterology

Volumn 30, Issue 1, 2014, Pages 84-96

  Blonski, Wojciech ^a   Buchner, Anna M ^b   Lichtenstein, Gary R ^b  

^a United Health Services   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

anti TNF alpha antibodies; corticosteroids; immunomodulators; mesalamine; ulcerative colitis

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CORTICOSTEROID; CYCLOSPORIN; GOLIMUMAB; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHYLPREDNISOLONE; OLSALAZINE; PENTOSE; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE;

ABDOMINAL PAIN; ACNE; ANOREXIA; BONE MARROW TOXICITY; COHORT ANALYSIS; COLON MUCOSA; COLON RESECTION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ENZYME ACTIVITY; FEVER; FLATULENCE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEADACHE; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOTHERAPY; LATENT TUBERCULOSIS; LOSS OF APPETITE; MAINTENANCE THERAPY; MALE INFERTILITY; META ANALYSIS; MUSCLE CRAMP; NAUSEA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PARESTHESIA; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; REMISSION; REVIEW; RHINOPHARYNGITIS; RISK FACTOR; SHORT COURSE THERAPY; SYSTEMATIC REVIEW; T CELL LYMPHOMA; TREATMENT DURATION; TUBERCULIN TEST; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN;

6-MERCAPTOPURINE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZATHIOPRINE; COLITIS, ULCERATIVE; CYCLOSPORINE; GASTROINTESTINAL AGENTS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MESALAMINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84890442152     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000031     Document Type: Review

References (68)

1. Su C, Lichtenstein G. Ulcerative colitis. In: Feldman M, Friedman L, Brandt L, editors. Sleisenger and Fordtran's gastrointestinal and liver disease, 8th ed Philadelphia: Saunders Elsevier; 2006. pp. 2499-2549.
2. Langholz E, Munkholm P, Davidsen M, et al. Course of ulcerative colitis: Analysis of changes in disease activity over years. Gastroenterology 1994; 107:3-11.
3. Hendriksen C, Kreiner S, Binder V. Long term prognosis in ulcerative colitis: Based on results from a regional patient group from the county of Copenhagen. Gut 1985; 26:158-163.
4. Stonnington CM, Phillips SF, Zinsmeister AR, et al. Prognosis of chronic ulcerative colitis in a community. Gut 1987; 28:1261-1266.
5. Langholz E, Munkholm P, Nielsen OH, et al. Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. Scand J Gastroenterol 1991; 26:1247-1256.
6. Sonu I, Lin MV, Blonski W, et al. Clinical pharmacology of 5-ASA compounds in inflammatory bowel disease. Gastroenterol Clin North Am 2010; 39:559-599.
7. Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. The Cochrane database of systematic reviews 2012; 10:CD000543. Extensive meta-analysis of the efficacy and safety of 5-ASA formulations in active ulcerative colitis.
8. Lichtenstein GR, Ramsey D, Rubin DT. Randomised clinical trial: Delayedrelease oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing-ASCEND I and II combined analysis. Aliment Pharmacol Ther 2011; 33:672-678.
9. Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology 2009; 137:1934-1943; e1-3.
10. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: A randomised, double blind, placebo controlled study. Gut 2005; 54:960-965.
11. Frieri G, Pimpo MT, Palumbo GC, et al. Rectal and colonic mesalazine concentration in ulcerative colitis: Oral vs. oral plus topical treatment. Aliment Pharmacol Ther 1999; 13:1413-1417.
12. Naganuma M, Iwao Y, Ogata H, et al. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: Comparison of orally administered mesalamine and sulfasalazine. Inflamm Bowel Dis 2001; 7:221-225.
13. Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 10: CD000544. Extensive meta-analysis of the efficacy and safety of 5-ASA formulations in maintaining remission of ulcerative colitis.
14. Paoluzi OA, Iacopini F, Pica R, et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Aliment Pharmacol Ther 2005; 21:1111-1119.
15. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105:501-523; quiz 24.
16. Lennard-Jones JE, Longmore AJ, Newell AC, et al. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as outpatient treatment for ulcerative colitis. Gut 1960; 1:217-222.
17. Baron JH, Connell AM, Kanaghinis TG, et al. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J 1962; 2:441-443.
18. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130:935-939.
19. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study. Gastroenterology 2001; 121:255-260.
20. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974; 1:1067-1070.
21. Truelove SC, Willoughby CP, Lee EG, et al. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978; 2:1086-1088.
22. Meyers S, Sachar DB, Goldberg JD, et al. Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis. A prospective, randomized, double-blind clinical trial. Gastroenterology 1983; 85:351-357.
23. Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985; 89:1005-1013.
24. Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: Systematic review and meta-analysis. Am J Gastroenterol 2012; 106:590-599; quiz 600. Recent meta-analysis providing evidence for use of glucocorticosteroids in ulcerative colitis.
25. Truelove SC, Witts LJ. Cortisone and corticotrophin in ulcerative colitis. Br Med J 1959; 1:387-394.
26. Lennard-Jones JE, Misiewicz JJ, Connell AM, et al. Prednisone as maintenance treatment for ulcerative colitis in remission. Lancet 1965; 1:188-189.
27. Powell-Tuck J, Bown RL, Chambers TJ, et al. A controlled trial of alternate day prednisolone as a maintenance treatment for ulcerative colitis in remission. Digestion 1981; 22:263-270.
28. Sherlock ME, Seow CH, Steinhart AH, et al. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010; 10: CD007698.
29. Sandborn WJ, Travis S, Moro L, et al. Once-daily budesonide MMX(R) extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: Results from the CORE I study. Gastroenterology 2012; 143:1218-1226; e1-2. Recent data on treatment of ulcerative colitis with budesonide MMX in active ulcerative colitis.
30. Travis SP, Danese S, Kupcinskas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: Results from the randomised CORE II study. Gut 2013. Recent data on treatment of ulcerative colitis with budesonide MMX in active ulcerative colitis.
31. Osterman MT, Kundu R, Lichtenstein GR, et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: A meta-analysis. Gastroenterology 2006; 130:1047-1053.
32. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118:705-713.
33. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: Final report on controlled therapeutic trial. Br Med J 1974; 4:627-630.
34. Caprilli R, Carratu R, Babbini M. Double-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopathic proctocolitis. Preliminary report. Am J Dig Dis 1975; 20:115-120.
35. Rosenberg JL, Wall AJ, Levin B, et al. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975; 69: 96-99.
36. Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J (Clin Res Ed) 1982; 284:1291-1292.
37. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006; 55:47-53.
38. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35:360-362.
39. Mantzaris GJ, Sfakianakis M, Archavlis E, et al. A prospective randomized observer-blind 2-year trial of azathioprine immunotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol 2004; 99:1122-1128.
40. Chebli LA, Chaves LD, Pimentel FF, et al. Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis. Inflamm Bowel Dis 2010; 16:613-619.
41. Timmer A, McDonald JW, Tsoulis DJ, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 9:CD000478. Updated meta-analysis on efficacy of immunomodulators in maintaining remission of ulcerative colitis.
42. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54:1121-1125.
43. Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: A UK population-based case-control study. Am J Gastroenterol 2010; 105:1604-1609.
44. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: A prospective observational cohort study. Lancet 2009; 374:1617-1625.
45. Chaparro M, Ordas I, Cabre E, et al. Safety of thiopurine therapy in inflammatory bowel disease (IBD): Long-term follow-up study of 3,900 patients. Gastroenterology 2010; 138:S-671.
46. Kotlyar DS, Gisbert JP, Lewis JD, et al. Overall Incidence of Hepatosplenic T Cell Lymphoma in Patients with Inflammatory Bowel Disease on Thiopurines: A Meta-analysis of Three Population Based Studies. Abstract accepted for Digestive Disease Week Chicago, IL May 7-May 10, 2011 2011.
47. Khan N, Abbas AM, Lichtenstein GR, et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines-a nationwide retrospective cohort study. Gastroenterology 2013; 145:1007.e3-1015.e3. The most recent data on the risk of lymphoma in patients with ulcerative colitis treated with thiopurines.
48. Chang KH, Burke JP, Coffey JC. Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: A systematic review and meta-analysis. Int J Colorectal Dis 2013; 28:287-293. The most recent meta-analysis demonstrating equal efficacy of cyclosporine and infliximab in patients with severe ulcerative colitis.
49. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330:1841-1845.
50. D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120:1323-1329.
51. Shibolet O, Regushevskaya E, Brezis M, et al. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005; 1:CD004277.
52. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60:571-607.
53. Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006; 4:760-765.
54. Remicade (Infliximab). Prescribing information. Centocor Ortho Biotech Inc. Malvern, PA; 2009.
55. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130:940-987.
56. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353:2462-2476.
57. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; 3:CD005112.
58. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9:36-41; e1.
59. Kotlyar DS, Blonski W, Diamond RH, et al. Hepatosplenic T-cell lymphoma in inflammatory bowel disease: A possible thiopurine-induced chromosomal abnormality. Am J Gastroenterol 2010; 105:2299-2301.
60. Humira (adalimumab). Prescribing information. North Chicago, IL: AbbVie Inc; 2013.
61. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Results of a randomised controlled trial. Gut 2011; 60:780-787.
62. Sandborn WJ, Van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142:257-265; e1-3. This is an RCT demonstrating efficacy of adalimumab in active ulcerative colitis patients.
63. Reinisch W, Sandborn WJ, Panaccione R, et al. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis 2013; 19:1700-1709.
64. Sandborn WJ, Colombel JF, D'Haens G, et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: Subgroup analyses from ULTRA Aliment Pharmacol Ther 2013; 37:204-213. Long-term maintenance data in ulcerative colitis patients responding to ADA induction.
65. Simponi (Golimumab). Prescribing Information. Horsham, PA: Janssen Biotech, Inc; 2013.
66. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate to severe ulcerative colitis. Gastroenterology 2013; online first: Jun 2, 2013. Randomized clinical trial demonstrating efficacy of golimumab in active ulcerative colitis patients.
67. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2013; online first: Jun 13, 2013. Randomized clinical trial demonstrating efficacy of golimumab in maintaining remission in ulcerative colitis patients.
68. Blonski W, Lichtenstein GR. Medical treatment of ulcerative colitis. Gastroenterol Pol 2008; 15:359-367.